- Physician Alignment, Joint Ventures, M&A
- Vendors, Procurement, Supply Chain
- Pharmaceuticals, Biologics, Medical Devices
- Reimbursement, Payor Relations
- Licensure & Credentialing
- Regulatory Compliance, Fraud & Abuse
- Privacy & Security
- Academic & Research
- Tax-Exempt Organizations
- Seton Hall University School of Law, Health & Hospital Graduate Certificate, Compliance Issues for Healthcare Providers
- Apexus Advanced 340B Operations Certificate
Leadership & Professional Memberships
- American Health Lawyers Association, Lead Coordinator, Fraud and Abuse Practice Group
- New Jersey State Bar Association, Health Law Section, Chair, Publications Committee (2016)
- CMS Drug Price Proposal Would Harm Patients, Providers
- United Healthcare’s OptumRx Accused of Defrauding Benefit Plan
- Charity for Gain: DOJ Eyes Patient Assistance Program Fraud
- Hospitals Lose Challenge to Rate Cuts for Safety-Net Drugs
- Are Private Equity Firms the New Health-Care Fraud Target?
- 340B Payment Reduction Litigation: Are There Limitations to the HHS Secretary’s Rate-Setting Authority?
- Concern Over Medicaid Rebate Program Drug Misclassification: Is Enhanced Enforcement Authority Coming?
- Pending Court Ruling Could Be Pivotal in Health Care Fraud Cases
- Coping With Reduced 340B Reimbursement for Safety Net Hospitals: Compliance and Budgetary Impacts
- New Year’s Changes to the 340B Discount Drug Program Raise Compliance Concerns as New Billing Modifiers and Payment Reductions Take Effect
- Flexibility Born of Necessity: The Case for an Inclusive Academic Medical Centers Exception in an Era of Shifting Financial Realities
- The First Step is (Re)Admitting that You Have a Problem: The Readmissions Risk Adjustment Debate and Successful Strategies for Reducing Re-Hospitalization
- Don’t Mail That Overpayment Disclosure Just Yet: Implications of CMS’ Final Rule Expanding the Writing, Signature and Holdover Provision of Stark Law Exceptions
- Hospice Care in the Crosshairs: The Growing Fraud and Abuse Enforcement Threat to Hospice Providers
- OIG Reports Signal Movement on Medicare Hospice Payment
- Physicians at Risk of Losing Rights to Recover Reimbursements
- Payment Problems Still Plague Medicare Programs
- Fraud Claims Against Hospice Providers Increase; What Every Hospice and Nursing Home Provider Should Know
- What is Adequate Assignment Language to Confer Derivative Standing?
- Courts Curtail the Application of the Consumer Fraud Act to ‘Consumer Transactions’
- New Jersey
- New York
- United States District Court for the District of New Jersey
- United States District Court for the Southern District of New York
- United States District Court for the Eastern District of New York
Justin C. Linder
Justin C. Linder is a seasoned Life Sciences and Healthcare attorney with deep experience representing biopharmaceutical organizations, health systems, academic medical centers, integrated delivery networks and a variety of other entities across the full spectrum of the healthcare industry. Justin’s focus includes negotiating sophisticated rebate and pricing arrangements with pharmacy benefit managers and commercial insurers; pharmaceutical price reporting issues; healthcare M&A matters; and negotiating a variety of managed care, vendor, pharmaceutical distribution, GPO, healthcare technology and physician alignment agreements, with an emphasis on pay-for-performance clauses. Justin also provides practical regulatory and compliance counsel, specializing in state and federal fraud, abuse and privacy laws.
After graduating cum laude from Boston College Law School, he began his legal career at Drinker Biddle & Reath LLP, focusing on False Claims Act and Anti-Kickback litigation involving global biopharmaceutical manufacturers and health systems, became active in the Healthcare Bar and earned a Health and Hospital Law Graduate Certificate from Seton Hall University School of Law.
His early professional accomplishments included obtaining dismissal of a whistleblower complaint against one of New Jersey’s largest health systems alleging False Claims Act violations for purportedly improper Medicare billing practices pertaining to level of care determinations and retaliatory discharge.
To enhance his healthcare acumen, Justin joined the Health Law departments of Brach Eichler, L.L.C. and, subsequently, McCarter & English, LLP, where he built a healthcare transactional and regulatory practice representing a broad range of industry stakeholders, including health systems, ambulatory surgery centers, academic medical centers, integrated delivery networks, home health and hospice providers, physician groups and real estate investment trusts, among many others.
A four-month secondment on-site at St. Joseph’s Healthcare System as Associate General Counsel afforded Justin the opportunity to obtain significant institutional knowledge, manage the system’s 340B discount drug program and collaborate closely with C-Suite executives.
His recent experience counseling management regarding the efficient and compliant delivery of pharmaceutical market access and prescription fulfillment solutions on behalf of global biopharmaceutical manufacturers and pharmacies as Vice President and General Counsel of Asembia LLC (the flagship enterprise of a group purchasing organization, a specialty pharmaceutical hub services and health information technology company, a pharmaceutical distributor, a specialty pharmacy consulting company and a licensed non-dispensing pharmacy), will add value to the services we provide our healthcare and life sciences clients.
Justin continues to publish articles concerning current healthcare topics in nationally distributed periodicals on a regular basis. He presently is serving an appointment as a leader in the American Health Lawyers Association’s Fraud and Abuse Practice Group, where he maintains access to a variety of resources and to industry and governmental leaders, an important asset that provides valuable insights regarding industry trends and enforcement priorities.
As former General Counsel of a healthcare services company, Justin is acutely aware that the current uncertainty in the healthcare market, coupled with an ever-evolving reimbursement environment, is dramatically altering the strategies and budgets of industry legal departments. He firmly believes that outside counsel must adapt to these changing times and develop solutions which enable clients to reduce their legal budgets without compromising the quality of the services upon which they rely.
Based on his in-depth background representing the various stakeholders within the healthcare industry, Justin possesses a multifaceted perspective, enabling him to anticipate clients’ critical legal and performance hurdles and to recommend effective solutions to achieve their business goals while reducing risk.
- Presenter, “340B’s Tumultuous Year: Program Status and Trends in Auditing, Compliance and Reimbursement,” American Health Lawyers Association Fraud & Compliance Forum, Baltimore, MD (September 27, 2018)
- Presenter, “340B Drug Program: An Overview, Manufacturers’ Perspective,” Internal Nationwide CLE Presentation for In-House Counsel of Novartis, Sandoz & Alcon Pharmaceutical Companies (July 20, 2016)
- Presenter, “Hospice Care in the Crosshairs: What Hospice Providers and Their Partners Need to Know to Avoid Becoming a Target of Healthcare Fraud Enforcement,” Home Care & Hospice Association of NJ 2016 Annual Conference (June 6, 2016)
- J.D., 2007, cum laude
Boston College Law School
Saul Lefkowitz National Intellectual Property Moot Court
- B.A., 2003 magna cum laude
University of Vermont
Phi Beta Kappa